Information Provided By:
Fly News Breaks for June 25, 2019
NTRA
Jun 25, 2019 | 07:08 EDT
Canaccord analyst Mark Massaro raised his price target on Natera to $32 from $30 following the company's announcement of a 3,000 patient, multi-center, prospective study to evaluate its Prospera test for kidney transplanted rejection. The analyst said the company is executing well in its base NIPT business and is making strong advancements in its oncology and transplant pipeline. Massaro reiterated his Buy rating on Natera and said it remains a top pick.
News For NTRA From the Last 2 Days
There are no results for your query NTRA